|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 882.00 INR | -0.37% |
|
+1.60% | -3.54% |
| Jan. 23 | Indian Companies Receive Approval for Generic Versions of Wegovy and Ozempic | FW |
| Jan. 23 | Zydus Lifesciences says USFDA inspection closed with 2 observations for Ankleshwar unit-2 plant | RE |
Main competitors
| 1m. Revenue rev. | 4m. EPS revision | 4m. Revenue rev. | 1y. EPS revision | 1y. Revenue rev. | Visibility | Nbr of analysts | ||
|---|---|---|---|---|---|---|---|---|
 | 30 | |||||||
| 38 | |||||||
| 11 | |||||||
| 36 | |||||||
| 6 | |||||||
| 1 | |||||||
| 11 | |||||||
| 12 | |||||||
| 8 | |||||||
| 16 | |||||||
| 5 | |||||||
| 13 | |||||||
| - | - | - | - | ||||
| 2 | |||||||
| 4 | |||||||
| - | - | ||||||
| Average | 14 | |||||||
| Weighted average by Cap. | 21 |
- Stock Market
- Equities
- ZYDUSLIFE Stock
- Sector Zydus Lifesciences Limited
- Sector revisions
Select your edition
All financial news and data tailored to specific country editions
